论文部分内容阅读
目的:探讨伊马替尼(STI571)对慢性粒细胞白血病(CML)患者T细胞免疫功能的影响。方法:以30例CML患者为观察组,32例缺铁性贫血患者为对照组,用流式细胞术(FCM)检测患者骨髓体外加用STI571后CD3+、CD3+CD8-、CD3+CD8+内T淋巴细胞内INF-γ表达水平。结果:STI571干预后,观察组CD3+、CD3+CD8-、CD3+CD8+T淋巴细胞内IFN-γ水平明显降低,与干预前和对照组比较有统计学差异(P<0.05),而对照组干预前后CD3+、CD3+CD8-、CD3+CD8+T淋巴细胞内IFN-γ水平变化无统计学意义。结论:STI571能够降低初发CML患者T淋巴细胞内IFN-γ的表达,影响初发CML患者的细胞免疫功能,使免疫功能受到抑制。
Objective: To investigate the effect of imatinib (STI571) on T cell immune function in patients with chronic myeloid leukemia (CML). Methods: Totally 30 patients with CML were selected as the observation group and 32 patients with iron deficiency anemia as control group. Flow cytometry (FCM) was used to detect the expression of CD3 +, CD3 + CD8-, CD3 + CD8 + INF-γ expression level in lymphocytes. Results: After STI571 intervention, the level of IFN-γ in the CD3 +, CD3 + CD8- and CD3 + CD8 + T lymphocytes in the observation group was significantly lower than that in the control group (P <0.05) The levels of IFN-γin CD3 +, CD3 + CD8-, CD3 + CD8 + T lymphocytes before and after intervention did not change significantly. CONCLUSIONS: STI571 can reduce the expression of IFN-γ in T lymphocytes in patients with newly diagnosed CML and affect the cellular immune function in patients with newly diagnosed CML, and suppress the immune function.